By Counterforce Health Team in Myozyme (alglucosidase alfa) —

Renewing Myozyme (Alglucosidase Alfa) Coverage with Aetna CVS Health in Texas: 2025 Requirements and Timeline

Quick Answer: Myozyme Renewal Requirements

Aetna CVS Health requires annual prior authorization renewal for Myozyme (alglucosidase alfa) in Texas. Start your renewal 60-90 days before expiration. Submit updated diagnostic confirmation (GAA enzyme/genetic testing), specialist evaluation notes, treatment response documentation, and medical necessity letter. If denied, you have 180 days to appeal internally and can request external review through Texas Department of Insurance within 4 months of final denial.

First step today: Contact your metabolic specialist to schedule renewal assessment and gather required documentation.

Table of Contents

  1. When to Start Your Myozyme Renewal
  2. Required Documentation Checklist
  3. Medical Necessity Letter Requirements
  4. Submission Timeline and Process
  5. If Your Coverage Lapses
  6. 2025 Formulary Changes to Monitor
  7. Appeals Process in Texas
  8. Personal Renewal Tracker
  9. FAQ

When to Start Your Myozyme Renewal

Don't wait until the last minute—Myozyme renewals require extensive documentation and can take 30-45 days for standard decisions. Here are the key triggers to begin your renewal process:

Early Warning Signs (90 Days Before Expiration)

  • Your specialty pharmacy mentions upcoming authorization expiration
  • You receive a letter from Aetna CVS Health about renewal requirements
  • Your metabolic specialist's office schedules annual monitoring appointments

Optimal Timeline

90 days before expiration: Schedule comprehensive evaluation with your Pompe specialist 60 days before: Submit complete renewal packet to Aetna CVS Health 30 days before: Follow up if no decision received; prepare for potential appeal

Note: Texas law requires continuation of specialty drug coverage during valid appeals if interruption poses clinical risk.

Required Documentation Checklist

Aetna CVS Health requires specific evidence to demonstrate ongoing medical necessity for Myozyme. Missing documentation is the most common cause of renewal delays.

Core Requirements Table

Document Type What It Must Show Where to Get It Source
GAA Enzyme Assay Confirmed deficiency consistent with Pompe disease Original diagnostic lab Aetna Policy
Genetic Testing Pathogenic GAA mutations Genetics lab report Aetna Policy
Specialist Evaluation Current disease status, subtype, progression Metabolic/neurology specialist UHC Provider Guidelines
Functional Assessments 6MWT, MMT, FVC results showing response/stability Specialist office Clinical Guidelines
Treatment Response Objective evidence of benefit or disease stabilization Clinical notes, test results Monitoring Standards
Dosing Documentation 20 mg/kg every 2 weeks per FDA labeling Prescription records FDA Access Data

Additional Documentation

  • ICD-10 coding: Ensure E74.02 (Pompe disease) is documented in recent notes
  • Site of care confirmation: Letter from approved infusion center
  • Compliance records: Documentation of adherence to therapy schedule
  • Adverse event monitoring: Any infusion reactions or safety concerns

Medical Necessity Letter Requirements

Your specialist must provide a comprehensive medical necessity letter addressing Aetna's specific criteria. Here's what it must include:

Essential Components

  1. Confirmed Diagnosis: Reference to GAA enzyme deficiency and genetic confirmation
  2. Disease Subtype: Infantile-onset vs. late-onset Pompe disease classification
  3. Current Clinical Status: Functional assessments, respiratory status, cardiac involvement
  4. Treatment Response: Objective evidence of stabilization or improvement on Myozyme
  5. Risk of Discontinuation: Clinical consequences of stopping enzyme replacement therapy
  6. Dosing Rationale: Weight-based calculations and FDA-approved schedule
  7. Monitoring Plan: Ongoing assessment schedule and safety monitoring
Clinician Corner: Studies show that even 2-month treatment interruptions in Pompe disease result in significant, largely irreversible functional decline. Document this risk clearly in your medical necessity justification.

Submission Timeline and Process

Standard Submission Process

  1. Gather Documentation (30 days): Collect all required materials from your care team
  2. Submit via CVS Specialty (Day 1): Most Myozyme renewals go through CVS Specialty Pharmacy
  3. Aetna Review Period (30-45 days): Standard prior authorization review timeline
  4. Decision Notification (Day 30-45): Approval or denial with specific reasons

Expedited Review Option

For urgent clinical situations, request expedited review:

  • Timeline: 72 hours for decision
  • Criteria: Risk of serious deterioration without continued therapy
  • Documentation: Physician attestation of urgency required

If Your Coverage Lapses

Critical: There are no approved alternatives to bridge therapy gaps for Myozyme. Even short interruptions cause rapid, often irreversible functional decline.

Immediate Actions

  1. Contact your specialist immediately - Do not delay or attempt to manage gaps independently
  2. Emergency access programs - Your physician can contact Sanofi for compassionate use programs
  3. Hospital coordination - Ensure your infusion center has emergency protocols for supply disruption
  4. Appeal urgently - File expedited appeals if coverage lapses due to administrative delays

Bridge Options

  • Manufacturer programs: Sanofi may provide emergency access through Named Patient Programs
  • Hospital stock: Some centers maintain reserve inventory for critical situations
  • Financial assistance: Counterforce Health helps patients navigate emergency access and appeal processes during coverage gaps

2025 Formulary Changes to Monitor

Good news: Myozyme remains on Aetna's 2025 specialty drug formulary as a preferred specialty tier medication. However, monitor these potential changes:

What to Verify Annually

  • Prior authorization requirements: May become more stringent
  • Quantity limits: New restrictions on dosing or frequency
  • Site of care requirements: Changes to approved infusion locations
  • Formulary tier: Cost-sharing adjustments

Mid-Year Updates

Aetna typically implements formulary changes on January 1 or July 1. Check the Summary of Changes documents for any Myozyme-specific updates.

Appeals Process in Texas

If your Myozyme renewal is denied, Texas law provides strong appeal rights with specific timelines.

Internal Appeal Process

  • Deadline to file: 180 days from denial notice
  • Standard review: 30 days for pre-service decisions
  • Expedited review: 72 hours for urgent cases
  • Specialist review: Request physician in same specialty within 10 working days

External Review (IRO)

After final internal denial, you can request independent external review:

  • Deadline: 4 months from final internal denial
  • Timeline: 20 days standard, 5 days expedited
  • Cost: Paid by Aetna for fully insured plans
  • Filing: Through Texas Department of Insurance (1-800-252-3439)
From our advocates: We've seen Myozyme denials successfully overturned when families provided comprehensive functional assessment data showing disease progression without therapy. The key is demonstrating that interruption poses immediate clinical risk with objective evidence, not just physician opinion.

Personal Renewal Tracker

Use this template to track your annual Myozyme renewal:

Renewal Planning Checklist

□ 90 days out: Specialist appointment scheduled
□ 75 days out: GAA enzyme/genetic testing confirmed current
□ 60 days out: Medical necessity letter received
□ 60 days out: Complete packet submitted to CVS Specialty
□ 45 days out: Follow-up call if no decision received
□ 30 days out: Prepare appeal materials if needed
□ Authorization expiration date: _______________
□ New authorization received: _______________

Key Contacts

  • Metabolic Specialist: _______________
  • CVS Specialty Pharmacy: _______________
  • Aetna Member Services: _______________
  • Texas Department of Insurance: 1-800-252-3439

For patients and families navigating complex specialty drug renewals, Counterforce Health provides comprehensive support in turning insurance denials into successful appeals through evidence-backed strategies tailored to each payer's specific requirements.

FAQ

How long does Aetna CVS Health prior authorization take for Myozyme in Texas? Standard decisions take 30-45 days. Expedited reviews for urgent cases are completed within 72 hours.

What if my specialist is out-of-network with Aetna? You may need a referral to an in-network metabolic specialist, or your doctor can request a network adequacy exception if no qualified in-network providers are available.

Can I get a 90-day supply while my renewal is pending? Texas law requires continuation of coverage during valid appeals. Contact Aetna member services to request continuation of benefits during renewal review.

What counts as treatment response for Myozyme renewal? Stable or improved 6-minute walk test, manual muscle testing scores, forced vital capacity, and quality of life measures. Even disease stabilization (preventing decline) qualifies as treatment response.

Does step therapy apply to Myozyme renewals? Generally no, since Myozyme is first-line therapy for Pompe disease. However, payers may require documentation of diagnosis confirmation and appropriate dosing.

What if Aetna requires switching to Nexviazyme? For late-onset Pompe disease, some payers prefer Nexviazyme. Your specialist can provide medical justification for continuing Myozyme if clinically appropriate.

Sources & Further Reading

This guide is for educational purposes only and does not constitute medical or legal advice. Always consult with your healthcare provider and insurance company for personalized guidance. For additional help with insurance appeals and coverage issues, contact the Texas Department of Insurance at 1-800-252-3439 or visit tdi.texas.gov.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.